Astrazeneca Pharma India Ltd. (ASTRAZEN) Share Price Hits Fresh 52-Week Low
- September 1, 2026
- Posted by: Harsh Piplani
- Category: News
Astrazeneca Pharma India Ltd. at Rs 6,773, down 1.25% today, hit a fresh 52-week low of Rs 6,767. Market capitalisation stands at Rs 17,146.63 crore.
Astrazeneca Pharma India Ltd. Share Price fell to Rs 6,773 on 11 September 2026, down 1.25% for the day, after touching a fresh 52-week low of Rs 6,767. The stock’s market capitalisation stands at Rs 17,146.63 crore, placing it among the larger listed names in the Pharmaceuticals & Drugs space. For investors searching Astrazeneca Pharma India Ltd. Share Price Today or Astrazeneca Pharma India Ltd. Stock News, the verified data confirms a new one-year low but does not establish a company-specific catalyst.
The move is drawing attention because the stock opened at Rs 6,858.7, matched its day’s high at Rs 6,858.7, and then slipped to the session low of Rs 6,767 before trading marginally above that level. Turnover was Rs 0.04 crore. From a financial perspective, the company is trading at a P/E ratio of 101.09 and a P/B ratio of 18.96, while ROE stands at 23.02 and ROCE at 31.24. On Univest, that combination makes the stock relevant for both price-action watchers and investors comparing valuation against profitability.
Astrazeneca Pharma India Ltd. Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 6,773 |
| Previous Close | Rs 6,858.65 |
| Today's Move | Rs -85.65 (-1.25%) |
| Open | Rs 6,858.7 |
| High | Rs 6,858.7 |
| Low | Rs 6,767 |
| Turnover | Rs 0.04 crore |
| Market Capitalisation | Rs 17,146.63 crore |
Astrazeneca Pharma India Ltd. (ASTRAZEN) traded at Rs 6,773 versus the previous close of Rs 6,858.65, a fall of 1.25%. The stock opened at Rs 6,858.7, reached a high of Rs 6,858.7, touched a low of Rs 6,767.
Astrazeneca Pharma India Ltd. Share Price Today reflects a clear intraday slide from the opening zone to a fresh yearly low, with the stock remaining close to the lower end of the day’s range. That makes this a confirmed 52-week trough event, not just a routine decline, and explains why the stock is appearing in market searches and Stock Market Today screens.
The stock closed previously at Rs 6,858.65 and is currently at Rs 6,773, a decline of Rs 85.65 or 1.25%. It opened at Rs 6,858.7, which also marked the day’s high, while the day’s low was Rs 6,767, the same as the new 52-week low. That sequence suggests the session weakened after the open rather than recovering into strength. Turnover at Rs 0.04 crore shows a modest traded value backdrop to the move, while the market cap remains Rs 17,146.63 crore.
For readers tracking Astrazeneca Pharma India Ltd. Share News or Astrazeneca Pharma India Ltd. Share Price Live, the immediate takeaway is straightforward: the stock has broken to a fresh one-year low and is still trading below the opening level. In the absence of a verified catalyst in the supplied data, the price event itself is the confirmed reason the stock is trending in today’s Market News. That brings the focus to valuation, profitability and industry comparisons rather than a headline-driven explanation.
Astrazeneca Pharma India Ltd. (ASTRAZEN) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 17,146.63 crore |
| P/E Ratio | 101.09x |
| P/B Ratio | 18.96x |
| ROE | 23.02% |
| ROCE | 31.24% |
| EPS | Rs 67.85 |
| Book Value Per Share | Rs 361.68 |
| Dividend Yield | 0.52% |
Astrazeneca Pharma India Ltd. (ASTRAZEN) fundamental metrics show P/E 101.09x, P/B 18.96x, ROE 23.02%, ROCE 31.24%. These figures provide context only and are not a buy or sell signal.
Astrazeneca Pharma India Ltd. has a market capitalisation of Rs 17146.63 crore, which gives readers a sense of company size before judging valuation. On valuation, P/E at 101.09x, P/B at 18.96x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 23.02% and ROCE of 31.24%, helping investors compare shareholder returns and capital efficiency. Additional supplied metrics include EPS of Rs 67.85, book value per share of Rs 361.68, dividend yield of 0.52%, adding context to earnings, balance-sheet value and historical payout. Against the supplied same industry benchmark, these figures can be compared with benchmark median P/E of 32.42x, median ROE of 11.8%, median ROCE of 13.66%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 101.09x |
| Benchmark Median P/E | 32.42x |
| Benchmark Average P/E | 48.79x |
| Benchmark P/E Range | 3.4x to 701.57x |
| Company P/B Ratio | 18.96x |
| Benchmark Median P/B | 3.04x |
| Company ROE | 23.02% |
| Benchmark Median ROE | 11.8% |
| Company ROCE | 31.24% |
| Benchmark Median ROCE | 13.66% |
| Company Market Capitalisation | Rs 17,146.63 crore |
| Benchmark Median Market Cap | Rs 715.37 crore |
Astrazeneca Pharma India Ltd. (ASTRAZEN) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.
Astrazeneca Pharma India Ltd. (ASTRAZEN) has a P/E ratio of 101.09x, which is above the benchmark median of 32.42x, a difference of +211.81%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Astrazeneca Pharma India Ltd. (ASTRAZEN) has a ROE of 23.02%, which is above the benchmark median of 11.8%, a difference of +95.08%. Astrazeneca Pharma India Ltd. (ASTRAZEN) has a ROCE of 31.24%, which is above the benchmark median of 13.66%, a difference of +128.7%.
Track stocks falling to yearly lows through the Univest 52-week-low screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Glenmark Life Sciences Ltd. | ALIVUS | 17,087.94 | 28.34 | 4.9 | 18.41 | 24.61 |
| Suven Pharmaceuticals Ltd. | COHANCE | 16,949.06 | 160.51 | 4.43 | 4.02 | 6.12 |
| Jubilant Pharmova Ltd. | JUBLPHARMA | 16,230.75 | 46.4 | 2.29 | 5.97 | 8.69 |
| Alembic Pharmaceuticals Ltd. | APLLTD | 16,074.93 | 23.16 | 2.75 | 12.35 | 11.74 |
| Eris Lifesciences Ltd. | ERIS | 18,505.72 | 29.16 | 4.66 | 19.23 | 14.47 |
Astrazeneca Pharma India Ltd. (ASTRAZEN) has a P/E ratio of 101.09x compared with the displayed peer median of 29.16x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 23.02% compares with a peer median of 12.35% across the companies shown in the table. ROCE stood at 31.24% versus the displayed peer median of 11.74%, providing a capital-efficiency comparison. Astrazeneca Pharma India Ltd. (ASTRAZEN) has a market capitalisation of Rs 17,146.63 crore. Among the 5 peers shown, 1 have a larger market capitalisation.
Why Investors Are Watching Astrazeneca Pharma India Ltd.
- The stock touched a fresh 52-week low of Rs 6,767 and was trading at Rs 6,773, down 1.25% on the day.
- The session high matched the opening price of Rs 6,858.7, while the stock weakened toward the day’s low.
- Valuation remains elevated with a P/E of 101.09 and P/B of 18.96.
- Profitability metrics are stronger, with ROE at 23.02 and ROCE at 31.24.
- Within the same-industry benchmark of 199 companies, the stock trades above median valuation but above median return ratios too.
About Astrazeneca Pharma India Ltd.
Astrazeneca Pharma India Ltd. operates in the Healthcare sector and the Pharmaceuticals & Drugs industry. In listed-market terms, it is a sizeable pharmaceutical company with a market capitalisation of Rs 17,146.63 crore, placing it well above the same-industry median market cap of Rs 715.37 crore. The available data set does not add product-level or segment-level revenue details, but it does place the company firmly within India’s pharmaceutical and healthcare ecosystem.
Its recent financial profile shows meaningful scale, with quarterly revenue figures of Rs 5,263.1 crore, Rs 5,590.9 crore, Rs 6,115.7 crore, Rs 5,786.1 crore and Rs 6,827.9 crore across the latest supplied sequence from Jun 2025 to Jun 2026. The same sequence shows net profit of Rs 558.3 crore, Rs 542.2 crore, Rs 325.9 crore, Rs 448.8 crore and Rs 379.3 crore. On Univest, that makes Astrazeneca Pharma India Ltd. Company News relevant not only for daily price action but also for how the market values those financial outcomes.
Track Astrazeneca Pharma India Ltd. Share Price on Univest
Use Astrazeneca Pharma India Ltd. (ASTRAZEN) live share-price page, Univest 52-week-low screener, Univest market blogs to review live stock data, yearly-low lists and related market analysis.
On Univest, investors can track Astrazeneca Pharma India Ltd. Share Price, Astrazeneca Pharma India Ltd. Share Price Today, 52-week levels, market cap, valuation ratios, profitability metrics and peer positioning in one place. Univest also helps users follow Astrazeneca Pharma India Ltd. Latest News, Astrazeneca Pharma India Ltd. Stock Performance and sector-level comparisons across Healthcare and Pharmaceuticals & Drugs. For readers monitoring Share Market Today, Univest provides a structured way to watch price action without turning a single day’s move into a prediction.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
Why is Astrazeneca Pharma India Ltd. Share Price in focus today?
Ans. Astrazeneca Pharma India Ltd. Share Price is in focus because the stock touched a fresh 52-week low of Rs 6,767 and traded at Rs 6,773, down 1.25% from the previous close of Rs 6,858.65.
What is the latest Astrazeneca Pharma India Ltd. Share Price Today?
Ans. The latest Astrazeneca Pharma India Ltd. Share Price Today is Rs 6,773. During the session, the stock opened at Rs 6,858.7, touched a high of Rs 6,858.7 and a low of Rs 6,767.
Did Astrazeneca Pharma India Ltd. hit a fresh 52-week low?
Ans. Yes, the stock hit a fresh 52-week low of Rs 6,767 on 11 September 2026. It was trading at Rs 6,773 afterward, confirming a new one-year low in the current session.
How much did Astrazeneca Pharma India Ltd. fall today?
Ans. Astrazeneca Pharma India Ltd. fell by Rs 85.65 in today’s session, a decline of 1.25%. The move came from a previous close of Rs 6,858.65 to a current price of Rs 6,773.
What does the current price action show for Astrazeneca Pharma India Ltd.?
Ans. The day’s price action shows weakness after the open. The stock opened at Rs 6,858.7, which was also the session high, and then slipped to Rs 6,767 before trading slightly above that low.
What is the market capitalisation of Astrazeneca Pharma India Ltd.?
Ans. Astrazeneca Pharma India Ltd. has a market capitalisation of Rs 17,146.63 crore. That is above the same-industry median of Rs 715.37 crore and also higher than the industry average of Rs 14,192.13 crore.
Is Astrazeneca Pharma India Ltd. expensive compared with its industry?
Ans. Based on supplied benchmarks, the stock trades at a P/E of 101.09 versus the same-industry median of 32.42 and average of 48.79. Its P/B of 18.96 also exceeds the median 3.04 and average 4.35.
How strong are Astrazeneca Pharma India Ltd. profitability ratios?
Ans. The company’s ROE is 23.02 and ROCE is 31.24. Both are above the same-industry medians of 11.8 and 13.66, indicating stronger reported returns than many companies in Pharmaceuticals & Drugs.
What are the key earnings metrics for Astrazeneca Pharma India Ltd.?
Ans. The supplied data shows EPS at Rs 67.85, book value per share at Rs 361.68 and dividend yield at 0.52. These metrics help frame earnings power, accounting net worth and historical payout relative to price.
How does Astrazeneca Pharma India Ltd. compare with peers?
Ans. Astrazeneca Pharma India Ltd. has a market cap close to Glenmark Life Sciences and Suven Pharmaceuticals, but its P/E of 101.09 is above Glenmark, Jubilant, Alembic and Eris, while ROE and ROCE are stronger than several peers.
